ArticleScientific reports2026
The role and regulatory mechanism of USP25 in pancreatic microcirculatory disturbance in severe acute pancreatitis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the molecular mechanism by which USP25 contributes to pancreatic microcirculatory disturbance in severe acute pancreatitis (SAP). SAP was induced by retrograde injection of 4% sodium taurocholate into the pancreatic duct following adenoviral delivery of sh-USP25 to suppress USP25 expression. Renin activity, and serum concentration of angiotensin II, endothelin, and NO were recorded. Pancreatic histopathology was assessed via H&E staining. Microcirculatory disturbance was evaluated after FITC-RBC infusion by measuring red blood cell flow rate, flow velocity, and functional vessel count. An in vitro SAP model was established by treating rat pancreatic acinar cell AR42J with cerulein. USP25 and TRAF6 expression levels in tissues and cells were examined using qRT-PCR and Western blotting. Cell viability and death were assessed using the CCK-8 assay and Hoechst33342/PI staining respectively. Co-immunoprecipitation confirmed the interaction between USP25 and TRAF6. TRAF6 ubiquitination was quantified following MG132 treatment. USP25 was markedly upregulated in pancreatic tissues of SAP rats. USP25 inhibition alleviated pancreatic microcirculatory disturbance and ameliorated pancreatic injury. USP25 directly bound to TRAF6 and stabilized its protein level by reducing TRAF6 ubiquitination. In conclusion, USP25 promotes pancreatic microcirculatory disturbance in SAP by stabilizing TRAF6 through deubiquitination, revealing a critical USP25-TRAF6 regulatory axis that drives SAP progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.